

## **Allergy Therapeutics**<sup>PLC</sup>

**Allergy Therapeutics plc**  
("Allergy Therapeutics", "ATL", the "Company" or the "Group")

### **Publication of Interim Results Delayed**

**29 March 2023** Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, announces that it will not publish its interim results for the six-month period to 31 December 2022 by 31 March 2023.

On 29 December 2022, the Company announced a delay in the publication of its annual report and accounts for the year to 31 June 2022 due to delays in completing the audit. Consequently, the Company's shares were suspended from trading on 3 January 2023 and remain suspended.

The Company is actively working to finalise the audit and publication of its 2022 annual report and accounts and its interim results. Allergy Therapeutics remains in active discussions regarding its funding situation and will update the market in due course.

For further information on the Company, please visit the website: [www.allergytherapeutics.com](http://www.allergytherapeutics.com).

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK law by virtue of the European Union (Withdrawal) Act 2018.

- ENDS -

#### **For further information, please contact:**

##### **Allergy Therapeutics**

+44 (0) 1903 845 820  
Manuel Llobet, Chief Executive Officer  
Martin Hopcroft, Interim Chief Financial Officer

##### **Panmure Gordon (Nominated Adviser and Broker)**

+44 (0) 20 7886 2500  
Freddy Crossley, Emma Earl, Corporate Finance  
Rupert Dearden, Corporate Broking

##### **Consilium Strategic Communications**

+44 20 3709 5700  
Mary-Jane Elliott / David Daley / Davide Salvi  
[allergytherapeutics@consilium-comms.com](mailto:allergytherapeutics@consilium-comms.com)

#### **Notes for editors:**

##### **About Allergy Therapeutics**

Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite, and peanut.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rs@seg.com](mailto:rs@seg.com) or visit [www.rs.com](http://www.rs.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORPPUPUWUPWGR